A Phase 1b/2 Randomized Study of AVB-S6-500 plus Nab-paclitaxel and Gemcitabine in Patients with Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Aravive, Inc
Start Date
November 16, 2021
End Date
August 8, 2026
Administered By
Duke Cancer Institute
Awarded By
Aravive, Inc
Start Date
November 16, 2021
End Date
August 8, 2026